The Immune Cell Study

Currently Recruiting

7 Jul 2026

Up to $6,800

Melbourne, Australia

The study drug is a new medicine being developed to potentially treat type 2 inflammation. Type 2 inflammation is a specific type of response by the body’s immune system. While it’s meant to protect us, in some people it can become overactive and contribute to certain long-term health conditions. These include asthma and chronic obstructive pulmonary disease (COPD), which affect breathing; atopic dermatitis, also known as eczema, which causes dry, itchy skin; and chronic rhinosinusitis with nasal polyps, a condition that leads to long-lasting sinus problems and growths in the nose. Understanding type 2 inflammation can help researchers and doctors find better ways to treat these conditions and improve quality of life for people who live with them.  

Your involvement contributes to making future treatments more targeted, accessible, and patient-friendly—potentially helping thousands of people around the world. It’s a meaningful way to support medical progress and make a lasting impact on the lives of others. 

Apply now Speak with us 1300 084 021

Join our clinical trial

This is a first-in-human (FIH) study, meaning it is the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee. 

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions. 

Join our clinical trial image

Why participate?

  • Contribute to Research that supports inflammatory conditions. 
  • Help Make Treatments More Inclusive and Effective 
  • Be the Reason Better Treatments Move Forward 

Study schedule

 

Intake 1 In-clinic stay:

7 July 2026 – 12 July 2026

 Follow-up visits:

15 July 2026 – 4 November 2026
Approx. 6 visits during this period
Intake 1 In-clinic stay:

8 July 2026 – 13 July 2026

 Follow-up visits:

16 July 2026 – 5 November 2026
Approx. 6 visits during this period

Study dates are subject to change. Our team will confirm details with you during the screening process.

Trial details

Study duration

A total of 5 nights inpatient & 6 follow-up visits

Study medication

Administered via a subcutaneous injection

Additional eligibility

  • Weight above 50kg
  • Non-smokers or no smoking ≤2 cigarettes per day or ≤5 cigarettes per week in the last 6 months before Screening

Ethics

This study has been reviewed and approved by an independent ethics committee.

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $6,800 *with screening reimbursement.
Full details outlined in consent form.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

5 nights, 6 clinic visits

Medical condition

Not taking any medications

Register your interest

This form takes around 3–5 minutes to complete. Your information will remain confidential and is used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1800 243 733


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We regularly have studies that allow participants who are (social) smokers.

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Study Preferences

While longer studies generally have a higher reimbursement, there are also studies with multiple short stays that have high reimbursements.
Referral Information



Consent to Information Use and Future Contact